Pfizer Inc faces a new challenge as Enanta Pharmaceuticals sues over a patent infringement concerning Paxlovid in the EU.

Pfizer faces challenges from pricing pressures, a 2026 patent cliff, and weak R&D momentum. Click here to find out why I rate ...

Enata Pharmaceuticals is suing Pfizer in a European Union court, alleging Pfizer's Paxlovid Covid-19 antiviral violates one of its patents. Enata said its patent, published Wednesday in the European ...

Pfizer (PFE) stock in focus as Enanta Pharmaceuticals (ENTA) sues the pharma giant in the EU, claiming its COVID pill ...

Enata Pharmaceuticals is suing Pfizer in a European Union court, alleging Pfizer's Paxlovid Covid-19 antiviral violates one of its patents. Enata said its patent, published Wednesday in the European ...

Released Tuesday, the AAP's recommendations call for routine vaccination of children ages 6 months to 2 years, citing ...

Pfizer Inc. just got a price target bump from Citi. Following a robust Q2, Citi upgraded Pfizer's price target from $25 to ...

Following the company’s strong Q2 performance, Citi raised its price target on Pfizer Inc. (NYSE:PFE) from $25 to $26 on ...

Q2 2025 Earnings Call Transcript August 14, 2025 Traws Pharma, Inc. beats earnings expectations. Reported EPS is $-0.11, expectations were $-8.75. Operator: Ladies and gentlemen, thank you for ...

Cash and equivalents (GAAP) totaled $13.1 million as of Q2 2025. These 10 stocks could mint the next wave of millionaires › Traws Pharma (NASDAQ:TRAW), a clinical-stage biopharmaceutical company ...

Pfizer (PFE 0.06%) has been a terrible investment over the past three years. Revenue and earnings have generally moved in the wrong direction, as the company has been unable to fo ...